Group 1 - AnuoYuda Gene Technology (Beijing) Co., Ltd. submitted its Hong Kong IPO prospectus on March 25, which became invalid six months later on September 25, with CCB International and Guotai Junan International as joint sponsors [1] - AnuoYuda focuses on IVD medical devices and multi-omics life science research services based on molecular diagnostics, being a pioneer in NGS-based prenatal testing IVD products [2] - The company's clinical sequencing solutions include self-produced IVD test kits based on gene sequencing, gene sequencers, bioinformatics analysis software, as well as supporting technical services and laboratory design [2]

Group 1 - AnuoYada Gene Technology (Beijing) Co., Ltd. submitted its Hong Kong IPO prospectus on March 25, which became invalid after six months on September 25, with CCB International and Guotai Junan International as joint sponsors [1] - AnuoYada focuses on IVD medical devices and multi-omics life science research services based on molecular diagnostics, being a pioneer in NGS-based prenatal testing IVD products [2] - The company's clinical sequencing solutions include self-produced IVD test kits based on gene sequencing, gene sequencers, bioinformatics analysis software, as well as supporting technical services and laboratory design [2]

比亚迪元老创办的安诺优达递表港交所：三年亏4.3 亿，未来业绩挑战重重 3月25日，安诺优达基因科技（北京）股份有限公司（以下简称安诺优达）递表港交所，正式申报港股 IPO。 据招股书，安诺优达是一家聚焦于以分子诊断为基础的IVD医疗器械及多组学生命科学研究服务的公 司，亦是专精于基于NGS的产前检测IVD产品的行业先锋。公司的临床测序解决方案包括自产基于基因 测序的IVD检测试剂盒、基因测序仪及生物信息学分析软件，以及配套技术支持及实验室设计服务。 公司实控人为比亚迪创始人之一的夏佐全。 招股书显示，安诺优达的控股股东包括夏佐全、深圳市正轩安诺复琢投资合伙企业（有限合伙）、时丰 华富及正轩安诺持有安诺优达的股份比例，分别为9.95%、4.75%、20.74%及18.82%。 据悉，深圳市正轩安诺复琢投资合伙企业（有限合伙）的普通合伙人为深圳正轩，而夏佐全持有深圳正 轩97.25%的股份；时丰华富的普通合伙人为宁波美第欣投资管理有限公司，后者由深圳正轩全资拥 有；2021年10月21日，正轩安诺与夏佐全签订一致行动协议。 上述股东承诺，在行使所持安诺优达股份的投票权时保持一致行动。若正轩安诺与夏佐全存在分歧， ...